# US 8,772,023 B2 · Promoters for recombinant viral expression

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,772,023 B2
- Document ID: US8772023B2
- Status: Granted
- Kind: B2
- Application number: 13/131,586
- Filed: 2009-11-27
- Published: 2012-05-17
- Granted: 2014-07-08
- Earliest claimed: 2008-11-27
- Assignees: Bavarian Nordic A/S
- Applicants: Robin Steigerwald; Christine Meisinger-Henschel; Eva Felder
- Inventors: Robin Steigerwald; Christine Meisinger-Henschel; Eva Felder
- Web page: https://patentgrep.com/patent/US8772023B2

## CPC

- C12N 15/86: Viral vectors
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 35/00: Antineoplastic agents
- A61P 37/02: Immunomodulators
- A61P 37/04: Immunostimulants
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C12N 2710/24143: viral genome or elements thereof as genetic vector
- C12N 2799/023: where the vector is derived from a poxvirus
- C12N 2830/00: Vector systems having a special element relevant for transcription
- C12N 2840/60: from viruses
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention relates to a promoter selected from a group of nucleic acids consisting of (a) a nucleic acid having the nucleotide sequence of SEQ ID NO:1; (b) a nucleic acid having a nucleotide sequence derived from SEQ ID NO:1, wherein not more than 10 nucleotides have been added, deleted, substituted and/or inverted from the nucleic acid of SEQ ID NO:1; and (c) a nucleic acid sequence having at least 70% identity with the nucleic acid of (a); wherein the promoter has a length of up to and including 27 nucleotides and wherein the promoter according to options (b) and (c) exhibits at least the 70% of the promoter activity of SEQ ID NO:1 as measured by the amount of recombinant protein produced.

## Claims

### Claim 1

A poxvirus expression vector comprising a promoter,
wherein the promoter is operably linked to a heterologous nucleic acid encoding a protein, and
wherein the promoter comprises the nucleotide sequence of SEQ ID NO:1 or a nucleotide sequence in which no more than 3 nucleotides have been substituted from the nucleic acid of SEQ ID NO:1.

### Claim 2 (depends on 1)

The expression vector of claim 1, wherein the promoter comprises the nucleotide sequence of SEQ ID NO:1.

### Claim 3 (depends on 1)

The expression vector of claim 1, wherein the promoter comprises the nucleotide sequence of SEQ ID NO:33.

### Claim 4 (depends on 1)

The expression vector of claim 1, wherein the promoter comprises the nucleotide sequence of SEQ ID NO:34.

### Claim 5 (depends on 1)

The expression vector of claim 1, wherein the promoter comprises the nucleotide sequence of SEQ ID NO:2.

### Claim 6 (depends on 1)

The expression vector of claim 1, wherein the promoter comprises the nucleotide sequence of SEQ ID NO:3.

### Claim 7 (depends on 1)

The expression vector of claim 1, wherein the promoter comprises the nucleotide sequence of SEQ ID NO:4.

### Claim 8 (depends on 1)

The expression vector of claim 1, wherein the promoter comprises the nucleotide sequence of SEQ ID NO:5.

### Claim 9 (depends on 1)

The vector of claim 1, wherein the promoter in the polynucleotide is joined directly to the start codon ATG of the heterologous nucleic acid encoding a protein.

### Claim 10 (depends on 1)

The vector of claim 1, wherein the pox virus vector is a vaccinia virus vector.

### Claim 11 (depends on 10)

The vector of claim 10, wherein the vaccinia virus vector is a modified vaccinia virus Ankara (“MVA”) vector.

### Claim 12 (depends on 11)

The vector of claim 11, wherein the MVA vector has the capability of reproductive replication in vitro in chicken embryo Fibroblasts (“CEF”), but no capability of reproductive replication in the human keratinocyte cell line HaCaT, the human embryo kidney cell line 293, the human bone osteosarcoma cell line 143B, and the human cervix adenocarcinoma cell line HeLa.

### Claim 13 (depends on 1)

An isolated host cell comprising the vector of claim 1.

### Claim 14 (depends on 2)

An isolated host cell comprising the vector of claim 2.

### Claim 15 (depends on 3)

An isolated host cell comprising the vector of claim 3.

### Claim 16 (depends on 4)

An isolated host cell comprising the vector of claim 4.

### Claim 17 (depends on 5)

An isolated host cell comprising the vector of claim 5.

### Claim 18 (depends on 6)

An isolated host cell comprising the vector of claim 6.

### Claim 19 (depends on 7)

An isolated host cell comprising the vector of claim 7.

### Claim 20 (depends on 8)

An isolated host cell comprising the vector of claim 8.

### Claim 21 (depends on 9)

An isolated host cell comprising the vector of claim 9.

### Claim 22 (depends on 10)

An isolated host cell comprising the vector of claim 10.

### Claim 23 (depends on 11)

An isolated host cell comprising the vector of claim 11.

### Claim 24 (depends on 12)

An isolated host cell comprising the vector of claim 12.